1Goodwin D A,Meares C F,McCall M J,et al. Pretargeted immunoscintigraphy with chimeric antibodies [ J ]. J Nucl Med, 1987,28: 561.
2Boerman O C,Van Schaijk F G, Oyen W J G, et al. Pretargeted radioimmunotherapy of cancer: progress step by step [ J ]. J Nucl Med ,2003,44:400-411.
3Goodwin D A, Meares C F. Pretargeted peptide imaging and therapy [ J ]. Cancer Biother Radiopharm, 1999,14 : 145-152.
4Goldenberg D M. Targeted therapy of cancer with radiolabeled antibodies[J]. J Nucl Med,2002 ,43 :693-713.
5Rosebrough S F, Hartley D F. Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis [J]. J Nucl Med,1996, 37(8) :1380-1384.
8Sharkey R M, Karacay H, Cardillo T M, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods[ J ]. Clin Cancer Res ,2005,11:7109s-7121 s.
9Hnatowieh D J, Virzi F, Rusekowski M. Investigation of avidin and biotin for imaging applications[ J ]. J Nucl Med, 1987,28 (8) :1294- 1302.
10Zhang M,Zhang Z,Garmestani K,et at. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xeuografts[ J ]. Proc Natl Acad Sci USA ,2003,100(4) : 1891-1895.
二级参考文献27
1Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med,2002,43(11): 1507-1529.
2Grana C,Chinol M,Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer, 2002,86(2) :207-212.
3Axworthy DB,Reno JM,Hylarides MD,et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA, 2000,97(4): 1802-1807.
4Breitz HB,Weiden PL, Beaumier PL, et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med, 2000,41 (1): 131-140.
5Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood, 2001,98(8) :2535-2543.
6Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase Ⅰ/Ⅱ study results. Cancer Biother Radiopharm, 2000,15(1) :15-29.
7Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effctive in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA, 2003,100(4): 1891-1895.
8Graves SS, Dearstyne E, Lin Y, et al. Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res, 2003, 9( 10Pt 1) :3712-3721.
9Wilbur DS,Hamlin DK,Chyan MK,et al. Biotin reagents for antibody pretargeting. 5. Additional studies of biotin conjugate design to provide biotinidase stability. Bioconjug Chem, 2001,12(4) :616-623.
10Goshom S, Sanderson J,Axworthy D, et al. Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. Cancer Biother Radiopharm, 2001,16(2): 109-123.
7Jianga J, Parkerb CE, Fullerb JR. An immunoaffinity tandem mass spectrometry (iMALDI) assay for detection of Francisella tularensis[J]. Analytica Chimica Acta,2007,605(1):70-79.
8Li Y, Li Y, Shi F, et al. Rapid detection of Francisella tularensis by multiplex PCR[J]. Journal of Biotechnology, 2008,136: 763-765.
9McLendon MK, Apicella MA, Allen LAH. Francisella tularensis: taxonomy, genetics, and Immunopathogenesis of a potential agent of biowarfare[J]. Annu Rev Microbiol,2006,60:167 - 185.
10Porsch Ozcurumez M, Kischel N, Priebe H, et al. Comparison of enzyme - linked immunosorbent assay , Western blotting ,microagglutination, indirect immunofluorescence assay, and flow cytometry for serological diagnosis of tularaemia [J]. Clin Vaccine Immunol,2004,11 (6): 1 O01 - 1015.
